CM
ENGNW icon

Caption Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Caption Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-141,904
Closed -$420K – 1678
2025
Q4 		$420K Buy
141,904
+134,760
+1,886% +$308K ﹤0.01% 1269
2025
Q3 		$5.07K Buy
+7,144
New +$5.41K ﹤0.01% 1596

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Caption Management's ENGNW Position: Q1 2026 in Review

Caption Management sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2026, closing a stake of 141,904 shares — an estimated $420K sold.

Caption Management first reported a position in ENGNW in Q3 2025 and held it in 2 quarters. The position peaked at $420K in Q4 2025. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • Caption Management reported no remaining enGene Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 141,904 enGene Therapeutics Warrants shares in Q1 2026, an estimated $420K.
  • Caption Management first reported a position in enGene Therapeutics Warrants in Q3 2025 and held it in 2 quarters.
  • Caption Management's enGene Therapeutics Warrants position peaked at $420K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.